Celastrol alleviates SGLT2 inhibitor-induced diabetic hyperketonemia by inhibiting hepatic ketogenesis.
mice. Importantly, celastrol effectively ameliorates SGLT2i-induced hyperketonemia. In summary, celastrol curbs hepatic ketone overproduction in a PPARα-dependent manner, indicating its protective potential against SGLT2i-induced hyperketonemia.
Authors
- Lingxu Liu
- 方福德
- Yinghan Zhu (ORCID: https://orcid.org/0009-0003-6889-0134)
- Zeyu Guo (ORCID: https://orcid.org/0009-0003-8633-7148)
- Yang Tian (ORCID: https://orcid.org/0000-0002-6978-5673)
- Jinrui Zhang
- Minglong Zhang
- Zhenyu Ma
- Ran Zhang
- Li Yan
- Xiaojun Liu
- Yiting Wang
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- PubMed
- Published
- 2026-09-15
- DOI
- https://doi.org/10.3724/abbs.2026117
- Primary Topic
- Natural Compounds in Disease Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00